Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Date:9/19/2011

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that management will present at the JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 11:00 A.M. ET in New York, NY.  David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only.  Delcath will offer a live webcast and subsequent archived replay of its presentation, which may be accessed at http://www.delcath.com/investors/events/.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to di
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek ... that it has initiated the development of its lead ... and that it has selected Quotient Clinical, The Translational ... (UK) to run its early development programs. ... Trial Application (CTA) by the end of the third ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2
... SAN DIEGO, Jan. 31 TargeGen, Inc. ... multi-center Phase I/II clinical trial of,TG101348, an ... JAK2 in,patients with myeloproliferative diseases., (Logo: ... of JAK2 is implicated in the pathogenesis ...
... Mayo clinic in key role in treatment discovery, ... New York,based company Cytopia Limited (ASX: CYT) announced ... demonstrated potent activity in cells,isolated from patients with ... of diseases where there is over-production of,particular cells ...
Cached Medicine Technology:TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients 2JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients 2
(Date:8/1/2014)... 01, 2014 The North America Sports Drink ... North America, with analysis and forecast of revenue. The Sports ... around $5,021.9 million in 2012 to $6,243 million by 2018, ... Browse through the TOC of the North America Sports Drink ... provided. This also provides a glimpse of the segmentation in ...
(Date:8/1/2014)... Society of America (GSA) the nation,s largest ... has chosen Sean P. Curran, PhD, of the University ... Nathan Shock New Investigator Award. , This distinguished honor ... aging through basic biological research. It was established in ... of GSA and pioneer in gerontological research at the ...
(Date:8/1/2014)... of electronic reminders such as text messages, emails or ... adhere to a preadmission antiseptic showering regimen known to ... to a first-of-its-kind study published in the August issue ... Surgeons . , Each year approximately 400,000 SSIs occur ... according to data sources cited by study authors. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Chilton ... portal that aims to empower patients and their ... their health care by providing easy, secure access ... gives patients instant, web-based access to their health ... radiology results, medications, allergies, demographic information, visit history, ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 Ticket Down ... at Maple Lane Farms in Knoxville/Greenback, TN; Ingram Farms ... Whitehurst Cattle Farm in Archer/Gainesville, FL. Luke Bryan is currently ... with Lee Brice and Cole Swindell. Bryan is responsible for ... world each summer and this year, just because the summer ...
Breaking Medicine News(10 mins):Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:Electronic reminders can help patients prevent surgical site infections 2Health News:Electronic reminders can help patients prevent surgical site infections 3Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4
... Eliminates Need for Cadavers and Accelerates Physician TrainingGREAT ... maker of anatomically accurate surgical training models, is ... new Maxillary Clinical Sinus Trainer. This innovative ... to train ENT surgeons on their new FinESS(TM) ...
... is a Gift that Helps Doctors Improve Health CareWINSTON-SALEM, N.C., ... 30th, DrScore.com , the physician rating Web ... feedback by rating their doctors online. "The best gift patients ... in general is honest, constructive feedback," says Steve Feldman M.D., ...
... in French . , Montreal, March ... to reality, thanks to a discovery from scientists at ... According to a study published in the journal ... first to clone, produce and purify a protein important ...
... incisionless, non-invasive procedure treats patients with chronic reflux ... Center today announced that two surgeons from its ... Washington State on Monday, March 16. EsophyX ... gastroesophageal reflux disease, or GERD. The two ...
... What can you buy with a dollar anymore? ... and treatment for those who cannot afford to battle breast ... Brandon Mendelson and the 1 in 8 Foundation are challenging ... $1 and provide care and complete support for women and ...
... on factory farmsWASHINGTON, March 17 Nearly one year ... released its landmark recommendations on how America should reform ... Slaughter today introduced the Preservation of Antibiotics for Medical ... the Federal Food, Drug, and Cosmetic Act to withdraw ...
Cached Medicine News:Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 2Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 3Health News:Rate Your Doctor at DrScore.com for Doctor's Day 2Health News:Rate Your Doctor at DrScore.com for Doctor's Day 3Health News:Researchers clone key sperm-binding proteins 2Health News:Northwest Hospital Surgeons Perform First EsophyX Procedure in Washington State 2Health News:$1 Can Make The Difference 2Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 2Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 3Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: